sh-Polypeptide-1 for Hair Regrowth - Quick Reference Sheet

sh-Polypeptide-1 for Hair Regrowth

Created on 09/27/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / ChatGPT 6 – Audit

Sh-polypeptide-1 is a growth-factor protein used in scalp products and professional hair-regrowth treatments. Controlled human studies support added benefit with minoxidil or blood-derived scalp injections; standalone cosmetic-serum effectiveness remains unresolved. Product identity, activity, and delivery matter. Injection reactions and procedure burden accompany uncertain long-term safety. Lasting results and maintenance needs remain unresolved; hair regrowth is distinct from an established health or longevity benefit. (Full Review)

Protocol

No standalone standard
No validated standalone regimen
No maximum dose or titration schedule identified.
Studied topical approach
3,500 international units + 1 mL of 5% minoxidil
Basic fibroblast growth factor, twice daily for 6 months. Units cannot define cosmetic percentage without assay data.
Studied injected approach
8 sessions, every 1–2 weeks
DermaHeal Stem C’Rum HL: several peptides at 10 parts per million; no isolated-ingredient dose.
Time to effect
Time to assessment
3 and 6 months
Topical add-on photographs; topical-serum time to effect is unknown.
Improved survival of transplanted follicles
12 months
Bovine growth-factor regimen; indirect human evidence.
Reduced scalp flaking and inflammation
After 8 sessions
Uncontrolled mixture study with concurrent treatments.

Benefits

Contraindications
  • Known hypersensitivity to the ingredient or formulation
  • Pregnancy, breastfeeding, and people under 18
  • Active infection, open lesions, or unexplained inflammation at the application site
  • Known or suspected malignancy at the intended treatment site
Key Interactions
  • Minoxidil
  • Clot-prevention medicines (warfarin, apixaban, aspirin, clopidogrel; skin puncture)
  • Irritating topicals (tretinoin, salicylic acid)
  • Other growth-factor procedures (peptide injections, blood-derived preparations, microneedling)

Risk & Side Effects

  • Medium: Local reactions with invasive delivery
  • Low: Scarring or worsened hair loss after injections; Scalp infection after invasive delivery
  • Speculative: Ingredient-specific allergy or immune reactions; Stimulation of abnormal tissue growth; Disruption of normal follicle cycling

Monitoring

Marker Target Why
Scalp hair density No established target; hairs/cm² versus personal baseline Quantify regrowth
Hair shaft diameterNo established target; change from baselineAssess thickening
Scalp inflammationNo established numerical target; redness, pain, lesions versus baselineDetect local harm
Ferritin, if deficiency is suspectedNo sh-polypeptide-1-specific functional target; correction of confirmed deficiencyAssess another cause
Thyroid function, if clinically indicatedNo peptide-specific functional target; track diagnosed thyroid disorderAssess another cause

Cadence: Baseline; tolerability at 2–4 weeks; photographs and counts at 3 and 6 months; new scalp symptoms as they occur. Illustrative documentation schedule, not a validated treatment protocol.

Qualitative Assessment

  • Perceived coverage: Scalp visibility and styling ease.
  • Shedding and comfort: Shedding, itch, burning, and pain.
  • Treatment burden: Adherence, discomfort, and time commitment.